ABOUT THE EVENT
Date: Monday, March 2, 2026 11am–12pm EST
Event Location: Virtual
As drug development grows more complex, collaborative research models are reshaping how clinically meaningful questions are identified and addressed. Investigator-Initiated Trials (IITs) and collaborative-initiated studies are emerging as powerful complements to traditional pharma-sponsored development—unlocking innovation, accelerating clinical validation, and advancing precision medicine for patients.
In this webinar, leading oncology experts Dr. Javier Cortés and Dr. Antonio Llombart-Cussac will explore how collaborative-initiated trials are transforming the clinical research landscape and creating new opportunities for scientific and clinical impact.
Featured Speakers
MEDSIR Scientific Advisor
He has been very actively involved in clinical trials that have led to the approval of seven new treatments for metastatic breast cancer in Europe over the past decade, and he is deeply engaged in research on the treatment of this type of tumor, particularly the triple‑negative and HER2‑positive subtypes. He is a member of more than 150 scientific projects related to this disease, holding leadership positions in many of them. He serves as a reviewer for several leading medical journals, such as New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology, and Journal of Clinical Oncology, among many others.
He is also an active member of the Spanish, European, and American societies of Medical Oncology (SEOM, ESMO, ASCO, respectively). In addition, he is a member of the Scientific Committee of the European Society for Medical Oncology (ESMO); he served as chair of the breast cancer section at the ESMO 2020 Congress, and co‑chair of the same section at the 2020 American Association for Cancer Research (AACR) Congress, as well as in the immunotherapy area at the AACR 2021 Congress.
MEDSIR Sctientific Advisor
Dr. Llombart‑Cussac is a member of the leading European and American oncology scientific societies.
Trained at the Universities of Valencia and Navarra, he completed his medical residency at the Hospital Clínico de Valencia. He later undertook research stays at the Gustave Roussy Institute (1994–1997) and at MSKCC in New York (2001). He provided clinical services at the Valencian Institute of Oncology Foundation (1998–2005) and served as Head of the Medical Oncology Department at the Arnau de Vilanova Hospital in Lleida (2005–2011).
